Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
178 Leser
Artikel bewerten:
(0)

ACR: NEJM Article on Ending Breast Cancer Screening Programs Incomplete and Should Concern American Women

Finanznachrichten News

WASHINGTON, April 16, 2014 /PRNewswire-USNewswire/ -- The American College of Radiology (ACR) and Society of Breast Imaging (SBI) agree with statements by Andorno and Jüni, in their recent article published in the New England Journal of Medicine (NEJM), that women need clear information with which to discuss mammography with their doctor. Unfortunately, the NEJM article failed to meet this standard. The authors minimized the deadly consequences of their recommendations to the Swiss government. The disastrous results may take years to develop. If breast cancer screening were ended in this country, it would cost the lives of up to 20,000 American women each year. The lack of a counterbalancing perspective, in a major scientific journal, is surprising and concerning. American women should pay close attention to the breast cancer screening policies that may be considered for them.

If routine breast cancer screening of all women were ended in the United States, approximately 15,000 - 20,000 additional women each year would die from breast cancer. Thousands more would endure extensive and expensive treatments than if their cancers were found early by a mammogram. Restriction of current screening would also cost lives. In 2009, the United States Preventive Services Task Force (USPSTF) suggested that women ages 40-49 not receive routine annual screening and those 50-74 receive biennial screening. Analysis (Hendrick and Helvie), published in the American Journal of Roentgenology, using the Task Force's own methodology, showed that if these USPSTF guidelines were followed, approximately 6,500 additional women each year in the U.S. would die from breast cancer.

The NEJM authors' claim that mammography does not save many lives through early detection of tumors is false. According to National Cancer Institute data, since mammography screening became widespread in the mid-1980s, the U.S. breast cancer death rate, unchanged for the previous 50 years, has dropped well over 30 percent. Recent randomized control trials, particularly the largest (Hellquist et al) and longest running (Tabar et al) breast cancer screening studies in history respectively, have reconfirmed that regular mammography screening cut breast cancer deaths by roughly a third (not the 20 percent cited by Andorno and Jüni) in all women ages 40 and over - including women ages 40-49. A study (Otto et al) published in Cancer Epidemiology, Biomarkers & Prevention shows mammography screening cuts the risk of dying from breast cancer nearly in half. A recent study published in Cancer showed that more than 70 percent of women diagnosed with breast cancer in their 40s at major Harvard teaching hospitals were among the 20 percent of women who were not being screened. When discussing doing away with screening programs that have been proven to save thousands of lives each year, this information is critical.

The NEJM authors point to the Canadian National Breast Screening Study (CNBSS) to support claims of overdiganosis and lack of mammography effectiveness. Balanced information that the CNBSS has been widely discredited is not included. The World Health Organization long ago excluded the CNBSS from its analyses of screening mammography's impact of breast cancer mortality. Ina recent interview with CNN, the American Cancer Society echoed methodological concerns about the study. Breast cancer groups, such asBreastCancer.org, have alsocriticized this study and warned against following the author's recommendations.

Medical science, at present, cannot determine which cancers will advance to kill a woman and which will not. As recently covered in the New York Times, estimates of overdiagnosis or overtreatment are not based on data regarding real patients, but are guesses based on population data that may be wildly off-mark. A recent article published in The Oncologist shows that many studies regarding overdiagnosis and potential harms of mammography are not well-founded and that their conclusions cannot be taken as fact. Yet, the NEJM authors advocate that widespread screening programs be ended, which would result in thousands of unnecessary deaths each year, based on such guesses. The ACR and SBI cannot support such a step.

Every major American medical organization with expertise in breast cancer care, including the American Congress of Obstetricians and Gynecologists , American Cancer Society, American College of Radiology, National Accreditation Program for Breast Centers and Society of Breast Imaging recommend that women start getting annual mammograms at age 40. The ACR and SBI continue to stand by these recommendations.

Mammography can detect cancer early when it's most treatable and can be treated less invasively - which not only save lives, but helps preserve quality of life. For more information regarding the proven effectiveness of regular mammography screening at reducing breast cancer deaths, please visit www.MammographySavesLives.org.

SOURCE American College of Radiology

© 2014 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.